Author/Editor		Muzlovič, Igor
Title		Dodatno zdravljenje sepse
Translated title		Adjuvant tretment of sepsis
Type		članek
Source		In: Baklan Z, Reberšek-Gorišek J, Kotnik-Kervokljan B, editors. Zbornik predavanj in praktikum Bedjaničev simpozij z mednarodno udeležbo o temi Sepsa in septični šok; 2003 maj 31-31; Maribor. Maribor: Splošna bolnišnica Maribor,
Publication year		2003
Volume		str. 151-9
Language		slo
Abstract		Current clinical advances in the adjuvant treatment of sepsis include therapy with activated protein C, control of blood glucose between normal ranges and early agressive volumen replacement therapy to avoid cellular oxygen deficit. New attempt using low doses of corticosteroids remains to be proven in large controlled clinical studies. There are many promising experimental data on enhancing or inhibiting immune response using new drugs to neutralise microbial products or block their interaction with specific receptors on immune cells including lipopolysaccharide binding protein, CD14, TLR2, TLR4 or TLR6. Another option is to block some cyitokines like MIF or mediafors like profein 1(high mobility group). A major shift has occured introducing activated protein C (drotracogin alfa) in the treatment of severe sepsis and septic shock leading to significante reduction of the relative and absolute risk of death.
Descriptors		SEPSIS INSULIN PROTEIN C STEROIDS LIPOPOLYSACCHARIDES